Emergent Biosolutions (EBS) has issued an announcement.
Emergent BioSolutions Inc. secured key contract modifications with U.S. health authorities, bolstering its role in national preparedness. The company will supply additional ACAM2000® smallpox vaccines to the U.S. Strategic National Stockpile under a $99.9 million agreement, and it has also received a $30 million extension to provide more doses of its anthrax vaccine, CYFENDUS™. The news reinforces Emergent’s commitment to support public health through its partnership with the government.
For detailed information about EBS stock, go to TipRanks’ Stock Analysis page.
